Low-dose Dobutamine Infusion and Single-dose Tocilizumab in Acute Myocardial Infarction Patients With High Risk of Cardiogenic Shock Development - a 2x2 Multifactorial, Double-blinded, Randomized, Placebo Controlled Trial

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary) ; Dobutamine
Indications Myocardial infarction
Focus Pharmacokinetics
Acronyms DOBERMANN

Most Recent Events

05 Nov 2024 Results published in the Trials.
30 Oct 2024 Study protocol of Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development, published in the Trials.
22 Apr 2024 Planned End Date changed from 1 Mar 2025 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight